| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/0008-5472.CAN-10-3761 |
| P953 | full work available at URL | https://aacrjournals.org/cancerres/article-pdf/71/12/4280/2654508/4280.pdf |
| P698 | PubMed publication ID | 21527556 |
| P2093 | author name string | Jian Chen | |
| Mark Labow | |||
| Qiong Shen | |||
| L. Alex Gaither | |||
| P2860 | cites work | Characterization of the biological effects of a novel protein kinase D inhibitor in endothelial cells | Q24314735 |
| The RAS effector RIN1 directly competes with RAF and is regulated by 14-3-3 proteins. | Q24537123 | ||
| Protein kinase D regulates basolateral membrane protein exit from trans-Golgi network | Q24605796 | ||
| Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation | Q24629474 | ||
| Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors | Q27349020 | ||
| Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| A quantitative analysis of kinase inhibitor selectivity | Q28264038 | ||
| Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF | Q28280081 | ||
| BRAF mutation predicts sensitivity to MEK inhibition | Q29614281 | ||
| Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K | Q29614757 | ||
| COT drives resistance to RAF inhibition through MAP kinase pathway reactivation | Q29615032 | ||
| Hyperactive Ras in developmental disorders and cancer | Q29616397 | ||
| RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF | Q29616828 | ||
| Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer | Q29618030 | ||
| Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer | Q29618155 | ||
| High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886) | Q33717222 | ||
| Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway | Q34156402 | ||
| A novel protein kinase D inhibitor attenuates early events of experimental pancreatitis in isolated rat acini | Q34513533 | ||
| Protein kinase D3 (PKD3) contributes to prostate cancer cell growth and survival through a PKCepsilon/PKD3 pathway downstream of Akt and ERK 1/2. | Q34778930 | ||
| Protein kinase D signaling | Q36035199 | ||
| PKD at the crossroads of DAG and PKC signaling | Q36470256 | ||
| BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines | Q36732681 | ||
| Protein kinase D1: a protein of emerging translational interest | Q36813850 | ||
| Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model | Q36841356 | ||
| Is B-Raf a good therapeutic target for melanoma and other malignancies? | Q37048982 | ||
| PKD3 is the predominant protein kinase D isoform in mouse exocrine pancreas and promotes hormone-induced amylase secretion | Q37068055 | ||
| (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway | Q37112466 | ||
| Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas | Q37118264 | ||
| Targeting the RAF-MEK-ERK pathway in cancer therapy | Q37393116 | ||
| Protein kinase D isozymes activation and localization during mitosis | Q38848115 | ||
| Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease | Q39720433 | ||
| PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers | Q39859169 | ||
| Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer | Q39940069 | ||
| Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma | Q39971699 | ||
| Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor | Q40164535 | ||
| Essential role for protein kinase D family kinases in the regulation of class II histone deacetylases in B lymphocytes | Q40322638 | ||
| Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells | Q42478581 | ||
| Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination | Q43177478 | ||
| The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel | Q46825496 | ||
| Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas | Q47306076 | ||
| RAS oncogenes: the first 30 years. | Q55036584 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 4280-4291 | |
| P577 | publication date | 2011-04-28 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing reactivation of MAPK signaling | |
| Protein Kinase D3 Sensitizes RAF Inhibitor RAF265 in Melanoma Cells by Preventing Reactivation of MAPK Signaling | |||
| P478 | volume | 71 |
| Q35033377 | Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas |
| Q58547215 | DRUG-seq for miniaturized high-throughput transcriptome profiling in drug discovery |
| Q36200052 | Functional and therapeutic significance of protein kinase D enzymes in invasive breast cancer |
| Q38146707 | Melanoma mutagenesis and aberrant cell signaling |
| Q37450733 | Metastatic melanoma - a review of current and future drugs |
| Q26795735 | Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets |
| Q33818086 | PKD2 and PKD3 promote prostate cancer cell invasion by modulating NF-κB- and HDAC1-mediated expression and activation of uPA |
| Q37047974 | RAF265 inhibits the growth of advanced human melanoma tumors |
| Q34307356 | Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance |
| Q58420563 | Research Highlights |
| Q35859282 | Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies |
| Q33978378 | Understanding the biology of melanoma and therapeutic implications |
Search more.